Regeneron Pharmaceuticals Inc (REGN) : Premier Asset Managment scooped up 240 additional shares in Regeneron Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 18, 2016. The investment management firm now holds a total of 36,720 shares of Regeneron Pharmaceuticals Inc which is valued at $14,848,834.Regeneron Pharmaceuticals Inc makes up approximately 3.77% of Premier Asset Managment’s portfolio.
Regeneron Pharmaceuticals Inc closed down -5.19 points or -1.27% at $404.38 with 8,49,430 shares getting traded on Friday. Post opening the session at $406.61, the shares hit an intraday low of $394.5 and an intraday high of $411.576 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Fisher Asset Management reduced its stake in REGN by selling 2 shares or 0.33% in the most recent quarter. The Hedge Fund company now holds 613 shares of REGN which is valued at $247,885.Fjarde Ap-fonden Fourth Swedish National Pension Fund boosted its stake in REGN in the latest quarter, The investment management firm added 2,376 additional shares and now holds a total of 17,406 shares of Regeneron Pharmaceuticals Inc which is valued at $7,079,542. Regeneron Pharmaceuticals Inc makes up approx 0.16% of Fjarde Ap-fonden Fourth Swedish National Pension Fund’s portfolio.Livforsakringsbolaget Skandia Omsesidigt reduced its stake in REGN by selling 1,500 shares or 18.35% in the most recent quarter. The Hedge Fund company now holds 6,676 shares of REGN which is valued at $2,715,329. Regeneron Pharmaceuticals Inc makes up approx 0.13% of Livforsakringsbolaget Skandia Omsesidigt’s portfolio.Creative Planning boosted its stake in REGN in the latest quarter, The investment management firm added 7,992 additional shares and now holds a total of 10,599 shares of Regeneron Pharmaceuticals Inc which is valued at $4,198,688. Regeneron Pharmaceuticals Inc makes up approx 0.03% of Creative Planning’s portfolio.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.50 based on the information available during the earnings call on Feb 9, 2016. Analyst had a consensus of $3.33. The company had revenue of $1098.00 million for the quarter, compared to analysts expectations of $1171.42 million. The company’s revenue was up 36.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.79 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Downgraded by Wells Fargo to ” Market Perform” on Apr 20, 2016. Shares were Reiterated by Sun Trust Rbsn Humphrey on Mar 17, 2016 to “Neutral” and Lowered the Price Target to $ 410 from a previous price target of $450 .Shares were Downgraded by Chardan Capital Markets on Mar 16, 2016 to ” Sell” and Lowered the Price Target to $ 325 from a previous price target of $375 .
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.